Core Insights - Anteris Technologies reported significant advancements in 2025, focusing on the development of the DurAVR transcatheter heart valve (THV) and positioning itself for leadership in the structural heart market [3][4]. Financial Performance - The company's net operating cash outflows for 2025 were $77.8 million, reflecting increased clinical, regulatory, and manufacturing requirements to support the PARADIGM Trial [4]. - Research and Development (R&D) expenses totaled $69.1 million, which included costs for manufacturing upscaling, clinical trial preparations, and an increase in R&D personnel [6]. - Selling, general, and administrative expenses were reported at $26.1 million [6]. Clinical Developments - Anteris initiated the global pivotal PARADIGM Trial, building on prior experience treating 130 patients with the DurAVR THV, including complex cases [5]. - The company received FDA Investigational Device Exemption (IDE) approval in Q4 2025 to commence the PARADIGM Trial in the U.S. [5]. - The PARADIGM Trial aims to enroll approximately 1,000 patients to evaluate the safety and effectiveness of the DurAVR THV compared to existing transcatheter aortic valve replacements (TAVRs) [8]. Strategic Initiatives - Anteris completed capital raises totaling $320 million in early 2026, including a strategic investment from Medtronic to support the PARADIGM Trial and advance global commercialization of the DurAVR THV System [5]. - The company strengthened its operational infrastructure and advanced its quality management system, achieving ISO 13485 certification for DurAVR THV production [5]. Product Overview - The DurAVR THV is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate the performance of a healthy human aortic valve [11]. - The valve is made from Anteris' patented ADAPT tissue, which has been clinically used for over 10 years and is FDA-cleared [11].

Core Viewpoint - Anteris Technologies Global Corp. is initiating a public offering of $200 million in common stock, with an additional $30 million option for underwriters, alongside a private placement of up to $90 million to Medtronic plc, aimed at supporting growth and clinical strategy execution [1][2][3]. Group 1: Offering Details - The company is offering $200 million of its common stock through a proposed underwritten public offering, with a 30-day option for underwriters to purchase an additional $30 million [1]. - Anteris has agreed to sell up to $90 million of common stock to Medtronic in a private placement, contingent on the completion of the public offering [2]. - The shares in the public offering are being offered under a shelf registration statement filed with the SEC, effective January 8, 2026 [5]. Group 2: Use of Proceeds - The net proceeds from the offering and private placement will be used to support the next stage of growth, including the PARADIGM Trial for the DurAVR Transcatheter Heart Valve and expansion of manufacturing capabilities [3]. - A portion of the proceeds will also fund ongoing research and development for v2vmedtech, inc., with the remainder allocated to working capital and general corporate purposes [3]. Group 3: Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function, with a significant presence in both Australia and the USA [9]. - The company's lead product, the DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [10].

Core Points - Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders to September 11, 2025, to allow more time for stockholder participation [1][2] - The Board of Directors recommends voting FOR the proposals in the definitive Proxy Statement filed with the SEC on August 18, 2025 [2] - The company’s lead product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and utilizes patented ADAPT tissue technology [8] Voting Details - Stockholders who have already voted do not need to take further action as their votes will remain counted [3] - Proxies must be submitted by 11:59 p.m. Eastern time on September 10, 2025, for Internet or telephone submissions, and by the close of business on the same date for mail submissions [4] - CDI holders must direct CDN to vote by 5:00 p.m. Central time on September 9, 2025 [5] Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function [7] - The company is based in Australia with a significant presence in Minneapolis, USA, and is committed to delivering solutions for structural heart disease [7]